Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(02/03): 147-155
DOI: 10.1055/a-0664-7632
Review
© Georg Thieme Verlag KG Stuttgart · New York

“The Adrenal Gland: Central Relay in Health and Disease - Current Challenges and Perspectives 2018” – Cushing’s Disease

Günter K. Stalla
1   Department of Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany
,
Denis Ciato
1   Department of Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany
,
Christina Dimopoulou
1   Department of Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany
› Author Affiliations
Further Information

Publication History

received 14 May 2018
revised 14 July 2018

Publication Date:
21 August 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Background Despite advances in diagnostic and therapeutic approach, Cushing’s disease (CD) presents a challenging situation for the treating physician.

Aims To elucidate current challenges, present strengths and pitfalls of existing diagnostic tests, enlighten the need for new diagnostic approaches, appraise the effects of surgery and available pharmacological agents and identify future perspectives regarding CD.

Materials and methods Systematic search to PubMed and Medline databases for publications mainly over the last five years.

Results Mutations in the ubiquitin specific peptidase 8 gene have been recently identified in functional sporadic corticotroph adenomas causing CD. Since the prevalence of obesity and metabolic syndrome is rapidly increasing, new diagnostic tests are necessary to differentiate these conditions. Next to the traditional tests, a cutoff of preoperative ACTH/cortisol ratio, an ultrasensitive late night salivary cortisol assay and the desmopressin test have been suggested as valid tools for the diagnosis and differential diagnosis of CD. Transsphenoidal surgery with variable remission and recurrence rates presents the treatment of choice for CD. Medical therapy consists of adrenal-targeted drugs e. g. ketoconazole, metyrapone, etomidate and mitotane and pituitary-targeted drugs e. g. pasireotide, cabergoline and retinoic acid.

Conclusions CD is associated to a significant clinical burden, since numerous comorbidities persist after long-term biochemical control. These chronically ill patients show an increased mortality despite disease remission. Clinicians should treat comorbidities aggressively and seek for appropriate consultations. Structured consultation hours and expert excellence networks are needed in order to allow optimal, individualized care for affected patients, reverse increased morbidity and mortality and identify tumor recurrence early.

Key words

Cushing’s disease - signs and symptoms - diagnostic tests - transsphenoidal surgery - medical therapy - comorbidities
 

  • References

  • 1 Newell-Price J. Cushing's syndrome. Clin Med (Lond) 2008; 8: 204-208
    PubMedGoogle Scholar
  • 2 Newell-Price J, Bertagna X, Grossman AB. et al. Cushing’s syndrome. Lancet 2006; 367: 1605-1617
    CrossrefPubMedGoogle Scholar
  • 3 Pivonello R, Isidori AM, De Martino MC. et al. Complications of Cushing's syndrome: State of the art. Lancet Diabetes Endocrinol 2016; 4: 611-629
    CrossrefPubMedGoogle Scholar
  • 4 Perez-Rivas LG, Theodoropoulou M, Ferraù F. et al. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. J Clin Endocrinol Metab 2015; 100: E997-E1004
    CrossrefPubMedGoogle Scholar
  • 5 Reincke M, Sbiera S, Hayakawa A. et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015; 47: 31-38
    CrossrefPubMedGoogle Scholar
  • 6 Theodoropoulou M, Reincke M, Fassnacht M. et al. Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. Eur J Endocrinol 2015; 173: M73-M83
    CrossrefPubMedGoogle Scholar
  • 7 Perez-Rivas LG, Reincke M. Genetics of Cushing's disease: An update. J Endocrinol Invest 2016; 39: 29-35
    CrossrefPubMedGoogle Scholar
  • 8 Lacroix A, Feelders RA, Stratakis CA. et al. Cushing's syndrome. Lancet. 2015; 386: 913-927
    CrossrefPubMedGoogle Scholar
  • 9 Casanueva FF, Barkan AL, Buchfelder M. et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 2017; 20: 489-498
    CrossrefPubMedGoogle Scholar
  • 10 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
    CrossrefPubMedGoogle Scholar
  • 11 Stalla GK, Dimopoulou C. Clinical diagnosis: Signs, symptoms, epidemiology. In: Handbook of Cushing’s disease BioScientifica 2011
    PubMed
  • 12 Loriaux DL. Diagnosis and Differential Diagnosis of Cushing's Syndrome. N Engl J Med 2017; 376: 1451-1459
    CrossrefPubMedGoogle Scholar
  • 13 Schneider HJ, Dimopoulou C, Stalla GK. et al. Discriminatory value of signs and symptoms in Cushing's syndrome revisited: What has changed in 30 years?. Clin Endocrinol (Oxf) 2013; 78: 153-154
    CrossrefPubMedGoogle Scholar
  • 14 Biller BM, Grossman AB, Stewart PM. et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab 2008; 93: 2454-2462
    CrossrefPubMedGoogle Scholar
  • 15 Oßwald A, Plomer E, Dimopoulou C. et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. Eur J Endocrinol 2014; 171: 209-215
    CrossrefPubMedGoogle Scholar
  • 16 Dimopoulou C, Athanasoulia AP, Hanisch E. et al. Clinical characteristics of pain in patients with pituitary adenomas. Eur J Endocrinol 2014; 171: 581-591
    CrossrefPubMedGoogle Scholar
  • 17 Scommegna S, Greening JP, Storr HL. et al. Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease. J Endocrinol Invest 2005; 28: 231-235
    CrossrefPubMedGoogle Scholar
  • 18 Minetto M, Reimondo G, Osella G. et al. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing’s syndrome. Osteoporos Int 2004; 15: 855-861
    CrossrefPubMedGoogle Scholar
  • 19 Ohmori N, Nomura K, Ohmori K. et al. Osteoporosis is more prevalent in adrenal than in pituitary Cushing’s syndrome. Endocr J 2003; 50: 1-7
    CrossrefPubMedGoogle Scholar
  • 20 Mancini T, Kola B, Mantero F et al. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004: 61: 768–777
    PubMed
  • 21 Pivonello R, Faggiano A, Lombardi G. et al. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34: 327-339
    CrossrefPubMedGoogle Scholar
  • 22 Feelders RA, Pulgar SJ, Kempel A. et al. The burden of Cushing's disease: Clinical and health-related quality of life aspects. Eur J Endocrinol 2012; 167: 311-326
    CrossrefPubMedGoogle Scholar
  • 23 van Haalen FM, Broersen LH, Jorgensen JO. et al. Management of endocrine disease: Mortality remains increased in Cushing's disease despite biochemical remission: A systematic review and meta-analysis. Eur J Endocrinol 2015; 172: R14
    PubMedGoogle Scholar
  • 24 Colao A, Pivonello R, Spiezia S. et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-2672
    PubMedGoogle Scholar
  • 25 Berr CM, Stieg MR, Deutschbein T. et al. Persistence of myopathy in Cushing's syndrome: Evaluation of the German Cushing's Registry. Eur J Endocrinol 2017; 176: 737-746
    CrossrefPubMedGoogle Scholar
  • 26 Nieman LK, Biller BM, Findling JW. et al. Treatment of Cushing's syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831
    CrossrefPubMedGoogle Scholar
  • 27 Arnaldi G, Scandali VM, Trementino L. et al. Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology 2010; 92: 86-90
    CrossrefPubMedGoogle Scholar
  • 28 Boscaro M, Sonino N, Scarda A. et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87: 3662-3666
    PubMedGoogle Scholar
  • 29 Arnaldi G, Angeli A, Atkinson AB. et al. Diagnosis and complications of Cushing’s syndrome: A consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602
    CrossrefPubMedGoogle Scholar
  • 30 Invitti C, Manfrini R, Romanini BM. et al. High prevalence of nodular thyroid disease in patients with Cushing’s disease. Clin Endocrinol (Oxf) 1995; 43: 359-363
    CrossrefPubMedGoogle Scholar
  • 31 Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 2010; 92: 65-70
    CrossrefPubMedGoogle Scholar
  • 32 Leistner SM, Klotsche J, Dimopoulou C. et al. Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas. Eur J Endocrinol 2015; 172: 733-743
    CrossrefPubMedGoogle Scholar
  • 33 Bourdeau I, Bard C, Noel B. et al. Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87: 1949-1954
    PubMedGoogle Scholar
  • 34 Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing’s syndrome. Psychoneuroendocrinology 2002; 27: 367-383
    CrossrefPubMedGoogle Scholar
  • 35 Sonino N, Bonnini S, Fallo F. et al. Personality characteristics and quality of life in patients treated for Cushing’s syndrome. Clin Endocrinol (Oxf) 2006; 64: 314-318
    CrossrefPubMedGoogle Scholar
  • 36 Dimopoulou C, Ising M, Pfister H. et al. Increased prevalence of anxiety-associated personality traits in patients with Cushing's disease: A cross-sectional study. Neuroendocrinology. 2013; 97: 139-145
    CrossrefPubMedGoogle Scholar
  • 37 Lindsay JR, Nansel T, Baid S. et al. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 2006; 91: 447-453
    CrossrefPubMedGoogle Scholar
  • 38 Valassi E, Feelders R, Maiter D et al. Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN. Clin Endocrinol (Oxf) 2018
    PubMed
  • 39 Valassi E, Franz H, Brue T. et al. Diagnostic tests for Cushing's syndrome differ from published guidelines: Data from ERCUSYN. Eur J Endocrinol 2017; 176: 613-624
    CrossrefPubMedGoogle Scholar
  • 40 Barbot M, Trementino L, Zilio M. et al. Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. Pituitary. 2016; 19: 488-495
    CrossrefPubMedGoogle Scholar
  • 41 Selek A, Cetinarslan B, Canturk Z. et al. The utility of preoperative ACTH/cortisol ratio for the diagnosis and prognosis of Cushing's disease. J Neurosci Rural Pract 2018; 9: 106-111
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Sturmer LR, Dodd D, Chao CS. et al. Clinical utility of an ultrasensitive late night salivary cortisol assay by tandem mass spectrometry. Steroids. 2018; 129: 35-40
    CrossrefPubMedGoogle Scholar
  • 43 Vassiliadi DA, Tsagarakis S. DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome. Eur J Endocrinol 2018
    PubMed
  • 44 Oldfield EH, Doppman JL, Nieman LK. et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. New England Journal of Medicine 1991; 325: 897-905
    CrossrefPubMedGoogle Scholar
  • 45 Lopez J, Barcelo B, Lucas T. et al. Petrosal sinus sampling for diagnosis of Cushing’s disease: evidence of false negative results. Clinical Endocrinology 1996; 45: 147-156
    CrossrefPubMedGoogle Scholar
  • 46 Swearingen B, Katznelson L, Miller K. et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 2004; 89: 3752-3763
    CrossrefPubMedGoogle Scholar
  • 47 Jarial DS, Bhansali A, Gupta V. et al. Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH. Endocr Connect. 2018; 7: 425-432
    CrossrefPubMedGoogle Scholar
  • 48 Feng M, Liu Z, Liu X. et al. Tumour lateralization in Cushing's disease by inferior petrosal sinus sampling with desmopressin. Clin Endocrinol (Oxf) 2018; 88: 251-257
    CrossrefPubMedGoogle Scholar
  • 49 Aberle J, Schulze Zur Wiesch C, Flitsch J et al. Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing's disease in an obese population. J Endocrinol Invest 2018
    PubMed
  • 50 Kosilek RP, Schopohl J, Grunke M. et al. Automatic face classification of Cushing's syndrome in women - a novel screening approach. Exp Clin Endocrinol Diabetes 2013; 121: 561-564
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Caimari F, Corcoy R, Webb SM. Cushing's disease: Major difficulties in diagnosis and management during pregnancy. Minerva Endocrinol. 2018
    PubMed
  • 52 Pivonello R, De Leo M, Cozzolino A. et al. The Treatment of Cushing's Disease. Endocr Rev. 2015; 36: 385-486
    CrossrefPubMedGoogle Scholar
  • 53 Bertagna X, Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 2013; 98: 1307-1318
    CrossrefPubMedGoogle Scholar
  • 54 Dimopoulou C, Schopohl J, Rachinger W. et al. Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing's disease: Care reality in the Munich Metropolitan Region. Eur J Endocrinol 2013; 170: 283-292
    PubMedGoogle Scholar
  • 55 Tritos NA, Biller BM. Medical management of Cushing's disease. J Neurooncol. 2014; 117: 407-414
    CrossrefPubMedGoogle Scholar
  • 56 Rutkowski MJ, Flanigan PM, Aghi MK. Update on the management of recurrent Cushing's disease. Neurosurg Focus. 2015; 38: E16
    PubMedGoogle Scholar
  • 57 Patil CG, Prevedello DM, Lad SP. et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008; 93: 358-362
    CrossrefPubMedGoogle Scholar
  • 58 Liu JK, Fleseriu M, Delashaw Jr JB. et al. Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus. 2007; 23: E8
    PubMedGoogle Scholar
  • 59 Benveniste RJ, King WA, Walsh J. et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005; 102: 1004-1012
    CrossrefPubMedGoogle Scholar
  • 60 Feng M, Liu Z, Liu X. et al. Diagnosis and outcomes of 341 patients with Cushing's disease following transsphenoid surgery: A single-center experience. World Neurosurg 2018; 109: e75-e80
    CrossrefPubMedGoogle Scholar
  • 61 Qiao N. Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing's disease. Endocr Connect 2018; 7: R26-R37
    CrossrefPubMedGoogle Scholar
  • 62 Carr SB, Kleinschmidt-DeMasters BK, Kerr JM. et al. Negative surgical exploration in patients with Cushing's disease: Benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg 2017; 1-8
    PubMedGoogle Scholar
  • 63 Cebula H, Baussart B, Villa C. et al. Efficacy of endoscopic endonasal transsphenoidal surgery for Cushing's disease in 230 patients with positive and negative MRI. Acta Neurochir (Wien) 2017; 159: 1227-1236
    CrossrefPubMedGoogle Scholar
  • 64 Tritos NA, Biller BMK. Update on radiation therapy in patients with Cushing’s disease. Pituitary 2015; 18: 263-268
    CrossrefPubMedGoogle Scholar
  • 65 Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96: 1992-2003
    CrossrefPubMedGoogle Scholar
  • 66 Colao A, Boscaro M, Ferone D. et al. Managing Cushing’s disease: The state of the art. Endocrine 2014; 47: 9-20
    CrossrefPubMedGoogle Scholar
  • 67 Mehta GU, Ding D, Patibandla MR. et al. Stereotactic radiosurgery for Cushing disease: Results of an international, multicenter study. J Clin Endocrinol Metab 2017; 102: 4284-4291
    CrossrefPubMedGoogle Scholar
  • 68 Reincke M, Ritzel K, Oßwald A. et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. Eur J Endocrinol 2015; 173: M23-M32
    CrossrefPubMedGoogle Scholar
  • 69 Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab 2013; 98: 425-438
    CrossrefPubMedGoogle Scholar
  • 70 Valassi E, Franz H, Brue T. et al. Preoperative medical treatment in Cushing's syndrome: Frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 2018; 178: 399-409
    CrossrefPubMedGoogle Scholar
  • 71 Fleseriu M, Petersenn S. New avenues in the medical treatment of Cushing's disease: Corticotroph tumor targeted therapy. J Neurooncol. 2013; 114: 1-11
    CrossrefPubMedGoogle Scholar
  • 72 Cuevas-Ramos D, Fleseriu M. Treatment of Cushing's disease: A mechanistic update. J Endocrinol. 2014; 223: R19-R39
    CrossrefPubMedGoogle Scholar
  • 73 Ciato D, Mumbach AG, Paez-Pereda M. et al. Currently used and investigational drugs for Cushing´s disease. Expert Opin Investig Drugs 2017; 26: 75-84
    CrossrefPubMedGoogle Scholar
  • 74 Hamrahian AH, Yuen KC, Hoffman AR. AACE Neuroendocrine And Pituitary Scientific Committee. AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease. Endocr Pract. 2014; 20: 746-757
    CrossrefPubMedGoogle Scholar
  • 75 Castinetti F, Guignat L, Giraud P. et al. Ketoconazole in Cushing's disease: Is it worth a try?. J Clin Endocrinol Metab 2014; 99: 1623-1630
    CrossrefPubMedGoogle Scholar
  • 76 Verhelst JA, Trainer PJ, Howlett TA. et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35: 169-178
    CrossrefPubMedGoogle Scholar
  • 77 Fleseriu M, Petersenn S. Medical management of Cushing's disease: What is the future?. Pituitary. 2012; 15: 330-341
    CrossrefPubMedGoogle Scholar
  • 78 Corcuff JB, Young J, Masquefa-Giraud P. et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol 2015; 172: 473-481
    CrossrefPubMedGoogle Scholar
  • 79 Preda VA, Sen J, Karavitaki N. et al. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: A review. European Journal of Endocrinology 2012; 167: 137-143
    CrossrefPubMedGoogle Scholar
  • 80 Baudry C, Coste J, Bou Khalil R. et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 2012; 167: 473-481
    CrossrefPubMedGoogle Scholar
  • 81 Fleseriu M, Findling JW, Koch CA. et al. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 2014; 99: 3718-3727
    CrossrefPubMedGoogle Scholar
  • 82 Guelho D, Grossman AB. Emerging drugs for Cushing’s disease. Expert Opin Emerg Drugs 2015; 20: 463-478
    CrossrefPubMedGoogle Scholar
  • 83 Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment for Cushing’s disease. Clin diabetes Endocrinol 2016; 2: 16
    CrossrefPubMedGoogle Scholar
  • 84 ClinicalTrials.gov [Internet]. Safety and Efficacy of LCI699 for the Treatment of Patients with Cushing's Disease https://clinicaltrials.gov/ct2/show/NCT02180217?term = lci + 699&cond = Cushing + Disease&rank = 1
    PubMed
  • 85 ClinicalTrials.gov [Internet]. Safety and Efficacy of LCI699 in Cushing's Disease Patients https://clinicaltrials.gov/ct2/results?cond = Cushing + Disease&term = lci + 699&cntry = &state = &city = &dist =
    PubMed
  • 86 Salvatori R, DelConte A, Geer EB. et al. An open-label study to assess the safety and efficacy of levoketoconazole (COR-003) in the treatment of endogenous Cushing's syndrome. Adrenal Tumors, Glucocorticoid Regulation and Action San Diego 2015; FRI-376
    PubMedGoogle Scholar
  • 87 Castillo V, Theodoropoulou M, Stalla J. et al. Effect of SOM230 (pasireotide) on corticotropic cells: Action in dogs with Cushing's disease. Neuroendocrinology. 2011; 94: 124-136
    CrossrefPubMedGoogle Scholar
  • 88 Hofland LJ, van der Hoek J, Feelders R. et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152: 645-654
    CrossrefPubMedGoogle Scholar
  • 89 Petersenn S, Salgado LR, Schopohl J. et al. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 2017; 57: 156-165
    CrossrefPubMedGoogle Scholar
  • 90 Pivonello R, Petersenn S, Newell-Price J. et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: Results from a Phase III study. Clin Endocrinol (Oxf) 2014; 81: 408-417
    CrossrefPubMedGoogle Scholar
  • 91 Colao A, De Block C, Gaztambide MS. et al. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: Medical expert recommendations. Pituitary 2014; 17: 180-186
    CrossrefPubMedGoogle Scholar
  • 92 Pivonello R, Matrone C, Filippella M. et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004; 89: 1674-1683
    CrossrefPubMedGoogle Scholar
  • 93 Castillo VA, Gómez NV, Lalia JC. et al. Cushing's disease in dogs: Cabergoline treatment. Res Vet Sci 2008; 85: 26-34
    CrossrefPubMedGoogle Scholar
  • 94 Pivonello R, Ferone D, de Herder WW. et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89: 2452-2462
    CrossrefPubMedGoogle Scholar
  • 95 Páez-Pereda M, Kovalovsky D, Hopfner U. et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108: 1123-1131
    CrossrefPubMedGoogle Scholar
  • 96 Castillo V, Giacomini D, Páez-Pereda M. et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology. 2006; 147: 4438-4444
    CrossrefPubMedGoogle Scholar
  • 97 Pecori Giraldi F, Ambrogio AG, Andrioli M. et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab 2012; 97: 3577-3583
    CrossrefPubMedGoogle Scholar